Germany is facing growing criticism over proposed restrictions to Medical Cannabis prescriptions that could reshape access for patients and telemedicine providers. Introduced by the Federal Ministry of Health, the draft bill would significantly tighten how Medical Cannabis is prescribed in Germany, requiring in-person doctor visits and in-pharmacy pickups.
Currently, licensed doctors in Germany can prescribe Medical Cannabis either in person or through telemedicine, with patients able to receive their medication by delivery. If the new law passes, it would mark a major shift for Germany’s largest cannabis market in Europe, estimated by Prohibition Partners to exceed $787 million in 2025. Critics argue that restricting telemedicine will make Medical Cannabis harder to access for patients across Germany, particularly those who are chronically ill or live in rural areas.
Since recreational cannabis was legalized in April 2024, Germany has seen a surge in Medical Cannabis use. There are now an estimated 338,000 active Medical Cannabis patients, up from 250,000 the year before. Imports have soared, reflecting rising demand and easier access. However, the Ministry of Health argues that the rapid increase in Medical Cannabis prescriptions—many from private telemedicine platforms—lacks sufficient oversight.
The Ministry claims that requiring in-person evaluations will ensure safer use. Yet, many industry leaders in Germany disagree. They point out that most telemedicine platforms follow proper guidelines, offering consultations, ID checks, and follow-ups. Eliminating them could force patients back to the illicit market, undermining Germany’s broader cannabis reforms aimed at safety and regulation.
Bloomwell, a leading telemedicine provider in Germany, reports that only 13% of patients seeking Medical Cannabis prescriptions receive one from traditional doctors. This gap drives patients online, where they find physicians more knowledgeable about Medical Cannabis. Without these digital options, many in Germany could lose access to essential treatments for pain, anxiety, or chronic conditions.
Industry experts warn that the proposed law could shrink Germany’s Medical Cannabis market by nearly 50%, damaging investment and costing jobs. With companies like Aurora Cannabis and High Tide already expanding into Germany, the potential economic fallout could be significant.
Ultimately, the debate highlights a key tension in Germany’s evolving cannabis policy: how to balance safety with access. Supporters of Medical Cannabis hope lawmakers will amend the bill to preserve patient rights while maintaining oversight. The future of Medical Cannabis in Germany may well depend on finding that balance.
